Michael Brian Bell Sells 2,202 Shares of CareDx Inc (CDNA) Stock

CareDx Inc (NASDAQ:CDNA) CFO Michael Brian Bell sold 2,202 shares of the company’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $32.10, for a total transaction of $70,684.20. Following the completion of the sale, the chief financial officer now directly owns 77,930 shares of the company’s stock, valued at $2,501,553. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Michael Brian Bell also recently made the following trade(s):

  • On Thursday, May 9th, Michael Brian Bell sold 14,894 shares of CareDx stock. The shares were sold at an average price of $32.42, for a total transaction of $482,863.48.
  • On Friday, March 1st, Michael Brian Bell sold 13,000 shares of CareDx stock. The shares were sold at an average price of $31.36, for a total transaction of $407,680.00.

NASDAQ CDNA opened at $31.63 on Friday. The stock has a market cap of $1.33 billion, a P/E ratio of -24.15 and a beta of 1.09. CareDx Inc has a 52-week low of $10.31 and a 52-week high of $39.38.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.03). The firm had revenue of $25.98 million for the quarter, compared to analysts’ expectations of $24.27 million. CareDx had a negative return on equity of 52.93% and a negative net margin of 51.21%. As a group, analysts predict that CareDx Inc will post -0.52 EPS for the current fiscal year.

CDNA has been the subject of a number of research reports. BidaskClub cut shares of CareDx from a “strong-buy” rating to a “buy” rating in a report on Friday, March 29th. Piper Jaffray Companies upped their target price on shares of CareDx from $42.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, May 9th. HC Wainwright set a $30.00 target price on shares of CareDx and gave the company a “hold” rating in a report on Thursday, March 7th. Raymond James upped their target price on shares of CareDx from $38.00 to $46.00 and gave the company a “strong-buy” rating in a report on Friday, March 22nd. Finally, Jefferies Financial Group initiated coverage on shares of CareDx in a report on Friday, February 15th. They issued a “buy” rating and a $35.00 target price for the company. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company. CareDx currently has an average rating of “Buy” and an average target price of $40.17.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its holdings in CareDx by 7.0% during the fourth quarter. BlackRock Inc. now owns 2,491,800 shares of the company’s stock worth $62,644,000 after purchasing an additional 162,939 shares in the last quarter. Vanguard Group Inc raised its holdings in CareDx by 31.4% during the third quarter. Vanguard Group Inc now owns 1,700,864 shares of the company’s stock worth $49,070,000 after purchasing an additional 405,968 shares in the last quarter. Vanguard Group Inc. raised its holdings in CareDx by 31.4% during the third quarter. Vanguard Group Inc. now owns 1,700,864 shares of the company’s stock worth $49,070,000 after purchasing an additional 405,968 shares in the last quarter. Lord Abbett & CO. LLC raised its holdings in CareDx by 219.0% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,493,150 shares of the company’s stock worth $37,538,000 after purchasing an additional 1,025,020 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in CareDx by 700.5% during the first quarter. Wellington Management Group LLP now owns 802,069 shares of the company’s stock worth $25,280,000 after purchasing an additional 701,869 shares in the last quarter. 87.07% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Michael Brian Bell Sells 2,202 Shares of CareDx Inc (CDNA) Stock” was first posted by Enterprise Leader and is the property of of Enterprise Leader. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://theenterpriseleader.com/2019/05/25/michael-brian-bell-sells-2202-shares-of-caredx-inc-cdna-stock.html.

About CareDx

CareDx, Inc operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Read More: How accurate is the Rule of 72?

Insider Buying and Selling by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.